Home
PBMWW
PBMWW News

Latest Psyence Biomedical Ltd. Warrant (PBMWW) News on January 18, 2025

Psyence Biomed Announces Closing of $2.0 Million Private Placement

GlobeNewswire

22 days ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position

TipRanks

25 days ago

Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position

Psyence Biomed Announces $2.0 Million Private Placement

GlobeNewswire

a month ago

Psyence Biomed Announces $2.0 Million Private Placement

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

GlobeNewswire

a month ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

GlobeNewswire

a month ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Psyence Biomedical executes binding agreements with Optimi Health

TipRanks

a month ago

Psyence Biomedical executes binding agreements with Optimi Health

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

GlobeNewswire

a month ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

GlobeNewswire

a month ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

GlobeNewswire

2 months ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Market Exclusive

2 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

GlobeNewswire

2 months ago

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

GlobeNewswire

2 months ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

GlobeNewswire

2 months ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

GlobeNewswire

3 months ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

GlobeNewswire

3 months ago

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

GlobeNewswire

3 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

GlobeNewswire

3 months ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

GlobeNewswire

3 months ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

GlobeNewswire

3 months ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

GlobeNewswire

3 months ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

GlobeNewswire

4 months ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

GlobeNewswire

4 months ago

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

GlobeNewswire

4 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

GlobeNewswire

4 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

GlobeNewswire

4 months ago

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

GlobeNewswire

4 months ago

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

GlobeNewswire

4 months ago

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

GlobeNewswire

4 months ago

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)

GlobeNewswire

4 months ago

Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

GlobeNewswire

5 months ago

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

GlobeNewswire

5 months ago

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Newsfile

5 months ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

GlobeNewswire

5 months ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

GlobeNewswire

6 months ago

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

GlobeNewswire

6 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

GlobeNewswire

6 months ago

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

US home sales dip, Secret Service director resigns: Catalysts

Yahoo Finance Video

6 months ago

US home sales dip, Secret Service director resigns: Catalysts

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire

6 months ago

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

GlobeNewswire

8 months ago

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

GlobeNewswire

9 months ago

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

GlobeNewswire

9 months ago

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

GlobeNewswire

9 months ago

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

GlobeNewswire

10 months ago

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

GlobeNewswire

10 months ago

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

GlobeNewswire

10 months ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

GlobeNewswire

10 months ago

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

GlobeNewswire

10 months ago

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

GlobeNewswire

10 months ago

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

GlobeNewswire

10 months ago

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Tivic Enters Exclusive Distribution Agreement with Top 10 Medical Product Distributor for Mass Market Retail

Business Wire

a year ago

Tivic Enters Exclusive Distribution Agreement with Top 10 Medical Product Distributor for Mass Market Retail

King Charles III spends third day in London hospital after prostate surgery

AFP

a year ago

King Charles III spends third day in London hospital after prostate surgery

Whether or not the Fed cuts rates is not the right question

Yahoo Finance

a year ago

Whether or not the Fed cuts rates is not the right question

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

GlobeNewswire

a year ago

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia

GlobeNewswire

a year ago

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia

Banzai Executes LOI to Acquire Top Rated Lead Generation Platform, IGLeads

GlobeNewswire

a year ago

Banzai Executes LOI to Acquire Top Rated Lead Generation Platform, IGLeads

SYLA’s Rimawari-kun Platform’s Gross Merchandise Value Surpasses Five Billion Yen

GlobeNewswire

a year ago

SYLA’s Rimawari-kun Platform’s Gross Merchandise Value Surpasses Five Billion Yen

Fossil Group (NASDAQ:FOSL) adds US$10m to market cap in the past 7 days, though investors from five years ago are still down 90%

Simply Wall St.

a year ago

Fossil Group (NASDAQ:FOSL) adds US$10m to market cap in the past 7 days, though investors from five years ago are still down 90%

Arqit Quantum Inc. Announces Financial and Operational Results for the Fiscal Year 2023

GlobeNewswire

a year ago

Arqit Quantum Inc. Announces Financial and Operational Results for the Fiscal Year 2023

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

Simply Wall St.

a year ago

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

GlobeNewswire

a year ago

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

trivago (NASDAQ:TRVG) Is Doing The Right Things To Multiply Its Share Price

Simply Wall St.

a year ago

trivago (NASDAQ:TRVG) Is Doing The Right Things To Multiply Its Share Price

FG Group Holdings Reports Third Quarter 2023 Operating Results

GlobeNewswire

a year ago

FG Group Holdings Reports Third Quarter 2023 Operating Results

Cue Health Inc. (NASDAQ:HLTH) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Cue Health Inc. (NASDAQ:HLTH) Q3 2023 Earnings Call Transcript

Business Wire

a year ago

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

Business Wire

a year ago

CuriosityStream To Report Third Quarter 2023 Financial Results on November 9, 2023

Associated Press Finance

a year ago

Cherry Hill: Q3 Earnings Snapshot

GuruFocus.com

a year ago

Cherry Hill Mortgage Investment Corp (CHMI) Reports Q3 2023 Earnings: Net Income Rises to $13. ...

Share on Social Networks: